Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCYH9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,196
Award facts
- Contract value 100% obligated
- $41,196.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $41,196.32 to DMS Pharmaceutical Group Inc. for Stelara 90 mg/ml syringes on January 13, 2026, with an ultimate completion date of February 4, 2026. This firm fixed-price delivery order was issued without a set-aside designation, leveraging the woman-owned small business pharmaceutical wholesaler's established capability to supply specialized biologic agents to Department of Defense healthcare operations. DMS Pharmaceutical Group, headquartered in Park Ridge, Illinois, was selected based on its demonstrated performance as a critical pharmaceutical supplier within the federal military medical system.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning the company as a regional prime vendor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The IDC structure enables DLA to issue delivery orders for comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide, with the Stelara delivery order exemplifying the company's role in supplying specialty immunosuppressant biologic agents to support Department of Defense medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FCYH9?
SPE2DR26FCYH9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FCYH9 worth?
The government has obligated $41,196 on SPE2DR26FCYH9.
Is contract SPE2DR26FCYH9 an order under another contract?
Yes. SPE2DR26FCYH9 is a delivery order under SPE2DR25D9153, an indefinite delivery contract.
Was contract SPE2DR26FCYH9 competed?
The extent of competition for SPE2DR26FCYH9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award